J
Janet Hammond
Researcher at Hoffmann-La Roche
Publications - 6
Citations - 225
Janet Hammond is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Hepatitis C virus & Ribavirin. The author has an hindex of 3, co-authored 5 publications receiving 196 citations.
Papers
More filters
Journal ArticleDOI
A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients
Nguyet Minh Nguyen,Chau Nguyen Bich Tran,Lam Khanh Phung,Kien Thi Hue Duong,Huy Le Anh Huynh,Jeremy Farrar,Quyen Nguyen,Hien Tinh Tran,Chau Van Vinh Nguyen,Laura Merson,Long T. Hoang,Martin L. Hibberd,Pauline P. K. Aw,Andreas Wilm,Niranjan Nagarajan,Dung Thi Nguyen,Mai Phuong Pham,Truong Thanh Nguyen,Hassan Javanbakht,Klaus Klumpp,Janet Hammond,Rosemary Petric,Marcel Wolbers,Chinh Nguyen,Cameron P. Simmons +24 more
TL;DR: Although this trial, the first of its kind in dengue, does not support balapiravir as a candidate drug, it does establish a framework for antiviral treatment trials in d Dengue and provides the field with a clinically evaluated benchmark molecule.
Journal ArticleDOI
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Edward Gane,Paul J. Pockros,Stefan Zeuzem,Patrick Marcellin,Anna Shikhman,Coen Bernaards,Julian Zhou,Ellen S. Yetzer,Rosa Ballester,Cindy Dwyer,Xiao Tong,Isabel Najera,Anne Bertasso,Janet Hammond,Amy Kindrick,Peter N. Morcos,Patrick F. Smith,Saray Stancic,Nancy S. Shulman +18 more
TL;DR: Safety and tolerability of peginterferon‐based hepatitis C virus (HCV) infection therapy remains suboptimal, even when direct‐acting antiviral agents are added.
Journal ArticleDOI
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Donald M. Jensen,Michael J. Brunda,Robert Elston,Edward Gane,Jacob George,Katerina Glavini,Janet Hammond,Sophie Le Pogam,Isabel Najera,Sharon Passe,Anna Piekarska,Ignacio Rodriguez,Stefan Zeuzem,Tom Chu +13 more
TL;DR: This study examined interferon‐free combinations containing setrobuvir, a ritonavir‐boosted protease inhibitor (danoprevir/r) and ribavirin, with/without the nucleoside inhibitor mericitabine in HCV genotype (G)1 patients.
Patent
Combination of therapeutic agents for treating hcv infection
TL;DR: In this paper, a hepatitis C virus infection, liver fibrosis and/or impaired liver function were treated with hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof.
Patent
Combination therapeutic composition
TL;DR: In this article, a hepatitis C virus infection, liver fibrosis and/or impaired liver function were treated with hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof.